Arnoud Den Ouden Email & Phone Number

Hoofddorp, North Holland, Netherlands

Driving and operationalising country activity and local strategies, ensuring business and commercial goals are met. This will be achieved via close collaboration and effective cross functional working with the wider KKI Team, the Cluster, and of course with all key external stakeholders, HCPs and PAGs.

Brussels, Brussels Region, Belgium

As of August 2023, I'm proud to be leading the business of rare diseases for Pfizer Belgium & Luxembourg, managing a successful portfolio of inline brands, combined with the wonderful prospect of pioneering the science of breakthroughs and aspiring to be the world’s leading innovator in rare disease.

Brussels, Brussels Region, Belgium

Accountable for the Covid franchise for Belgium & Luxembourg. Working with a very talented team to partner with a variety of external and internal stakeholders on the prevention and treatment of covid-19.

Belgium

From the 3rd January 2022, I’m happy and excited to lead the Inflammation & Immunology (I&I) business and commercial organisation in Belgium, one of I&I’s largest and fastest growing markets in Mid-Sized Europe. Building on recent experiences in Germany, Sweden and Finland, this role holds responsibility for delivering the revenue and IBT targets, incl. full P&L management, and the development and execution of the annual and multi-year operating plan. In addition, focus will be on an evolving way of working with our customers and an increased focus on bringing forward several innovations in the services of the business and to patients. The I&I Belgium Lead is a member of the I&I Mid-Sized Europe Leadership Team and provides input and helps shape strategy and focus for I&I in this region. In addition, this role includes membership of the Country Leadership Team of Belgium, partnering with the other business unit leads and cross-functional partners, such as Medical, Finance, Access, Corporate affairs, etc..

Netherlands

From 1st May 2021, I’m leading the Inflammation & Immunology business for Sweden and Finland, as I&I SE-FI sub-Cluster Lead. This role holds responsibility for delivering the revenue and IBT targets for the sub-cluster, incl. full P&L management, and the development and execution of the annual and multi-year operating plan. In more detail, there’s a clear focus on the execution of commercial activities related to Xeljanz, Enbrel and Inflectra, as well as subsequent launch activities related to Medical Dermatology products. The I&I sub-Cluster Lead is a member of the I&I Mid-Size Europe Leadership Team and provides input and helps shape strategy and focus for I&I in this region. In addition, this role includes membership of the Country Leadership Teams of Sweden and Finland, partnering with the other business unit leads and cross-functional partners.

Global - Based In The Netherlands

From 1st January 2019, as the Global Commercial Performance Lead for the Inflammation & Immunology (I&I) portfolio, I’m providing commercial and strategic expertise and guidance for local implementation. With the focus on Enbrel and Biosimilars (eg Inflectra), I’m partnering with Country/Cluster I&I Leads across the world, and cross-functional partners (eg Finance, Pricing, Access, Medical), on country business reviews, forecasting and OP evaluations, to find incremental opportunities and assess/mitigate risks where needed. Additionally, I’m identifying country level capability needs/gaps and determining plans to address these.

Based In The Netherlands

From mid-July till early November I’ve stepped in temporarily to cover the I&I Germany Lead role, while continuing my current global role as CPL for Enbrel and Biosimilars. The role included oversight of the business (~$250M revenue P&L; ~100 colleagues) and particularly the Op Planning 2021 process. Additionally, I've been focusing on the execution of commercial activities related to Xeljanz, Enbrel and Inflectra, as well as subsequent launch activities related to Medical Dermatology products. The I&I Germany Lead is a member of the I&I IDM Leadership Team and provides input and helps shape strategy and focus for I&I in the IDM (International Developed Markets) region.

Global - Based In The Netherlands

From 1st December 2017, I've joined the Global Biosimilars Team as Regional Lead (Global Commercial Lead). In this new role I have been responsible for driving business performance by ensuring consistent commercial and operational support for the Biosimilars portfolio across all regions globally: Europe, AsiaPacific, Latin America, Canada, Greater China and Africa Middle East. In addition, I had specific operational responsibility for biosimilars in the Europe Region to achieve the ambitious business objectives agreed in the 2018-2020 Operating Plan. In this position , I reported to the Global Biosimilars Lead and have been a member of the Global Biosimilars Leadership Team. In addition, two colleagues in Europe continued to report to me and I have filled two additional positions on the regional team to support biosimilars across markets in the above regions. I continued to be based in the Netherlands.

Europe; Based In The Netherlands

As the Regional Business Director (RBD) Biosimilars, I’ve been focusing on our customers in relation to the biosimilars segment of the Pfizer PEH portfolio, to drive exceptional business performance and to meet ambitious business objectives for Europe, through knowledge, networking and innovation.Background:Biologics are medicines made from living cells through highly complex manufacturing processes. They must be handled and administered under carefully monitored conditions. Biologics are used to prevent, treat, diagnose, or cure a variety of serious and chronic illnesses including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases. A biosimilar is exactly what its name implies — it is a biologic that is “similar” to another biologic drug already approved by EMA or the FDA. Under European or U.S. law, a biosimilar is approved based on a showing that it is “highly similar” to an already approved biological product, known as a reference product.

Tadworth, Uk; Hurley, Uk

As we continued on our journey of fully integrating legacy Hospira into our Pfizer Essential Health (PEH) business, there was great excitement regarding the potential opportunities in 2016 at a business, people and capability level. To ensure a smooth journey and full engagement throughout this transition, I had been appointed as interim Project Lead per 1st December 2015.I have been accountable for the leadership of the Hospira UK business throughout 2016, as well as the leadership of the full integration process, with Integration Day on 3rd October and officially closing the project by December 2016. Hospira in the UK consisted of a very interesting business with three biosimilars (including one very promising) as well as a healthy portfolio of Sterile Injectables, with total revenues of approx. $55m and about 35 people. For PEH UK, this has been a critical project from June 2015 till November 2016 and I have been reporting into the Central Cluster Lead for Pfizer PEH Europe, which includes the UK and 6 other European countries.

United Kingdom

In this role, I have been responsible for UK Global Established Pharma Business Operations, working closely with our Business Unit Head and Leadership team on a day-to-day basis as well as on key topics such as business reviews, operating plans and key business events. In parallel, I have been leading a team of experts (14 colleagues in total) for Tendering in the UK, Pricing, Commercial Pharmacy Support and Market Analytics. This team has been driving revenues (tender business), managing significant rebates and deals, supporting the marketing and sales business with pricing and analytics expertise, as well as generating direct and incremental value by creating and implementing new operational ideas, tools and processes.

Europe

Peri-LoE Planning has been and still is critical to Pfizer’s future success. Between 2009 and 2014, a significant amount of "blockbusters" has reached the end of their patent and faced their loss of exclusivity (LoE). Therefore, Pfizer Established Products Europe had committed additional resources to Peri-LoE Planning in its new organizational structure. So from December 1st 2009, I have been working fulltime on Peri-LoE Planning, in close collaboration with:- the 16 EU countries- my Global Peri LoE team members in New York- and the LoE Captains of the in-line Regional Brand Teams teams, from the other Pfizer Business Units.The goal of my job was to develop and lead successful commercial strategies to maximise the Peri-LOE assets in Europe, with major focus on Pfizer’s largest brand, Lipitor, and other key brands. And to ensure an efficient implementation of strategies. I have worked in close cooperation with other Pfizer Business Units to ensure strategic continuity and preparation of proper plans for the key products when they lose patent protection and transition into the Established Products.I therefore acted as a member of the Global Peri-LOE team, leader of a virtual cross-functional team in Europe and as the primary point of contact to European countries.Peri LoE Management background:Peri-LoE management is a combined effort along key value drivers across Business Units, including dual products (duplicate licenses availability, launch timing, external partnering), channel strategies (channel relationships, channel offering, launch strategy) and Promotion (positioning, targeting, stakeholder management, non-personal selling options). And besides that, it needs a close working relationship with the enabling functions (Regulatory, Manufacturing, Legal, Product Enhancement, Corporate Tax, Finance, Pricing & Market Access), in order to initiate key strategies and activities along the relevant Peri LoE timelimes.

Northern Europe

My responsibilities included a variety of projects, from divesting an older oncology product, exploring Business Development opportunities, sharing best practices regarding Tendering in Europe as well as Peri-LoE priorities, such as ensuring dual products for our upcoming LoE's (products losing patent exclusivity).

Rotterdam, Netherlands

Responsiblities (int.al.): Strategic customerplans and customermanager of GP’s, pharmacists, specialists and regional networks (especially. 1st line and transmural care).National Sales Manager Spiriva, co-promotion with partner Boehringer Ingelheim. Sparringpartner of Marketing in relation to the product- and customerstrategy. Selection and final decision on candidates for the specific fieldforce functions. Shaping and implementation of our development program for accountmanagers.

Rotterdam Area, Netherlands

Sales/business responsible for one of the four regions in the Netherlands: South-West NL. Linemanager of four salesmanagers, each responsible within their district for the realisation of their sales- and customersatisfaction goals. FTE-responsibility: 50 people.

Rotterdam, Netherlands

Strategic projects towards a better, customer focussed, Pfizer.Managing Customer Networks:Identifying regional and national networks, the interaction between them and provide guiding principles on the proces how to organise customer (related) departments for these networks. Furthermore, we will define business needs (requirements) on infrastructure, people and training, to be followed up by other projects.Customer Segmentation:Implementation of the customer segmentation, based on new regional structures and segmentation of the customer based on a strategical and economical value.

Netherlands

Salesmanager of two teams of five Regional Account Managers (Cardiovascular & Pain/Psychiatry/COPD). Process responsible for regional and national formulary- and FTO-policy (1st & 2nd line).

Pfizer Netherlands, Rotterdam

Build and maintain sustainable relationships with pharmaceutical wholesalers and parallel import/export firms in the Netherlands and negotiating margin-and price-agreements with them, for all Pfizer products; Responsible for all contracts with the buying groups of hospitals and individual hospitals in the Netherlands.

Region: Middle- And East Netherlands.

Account Manager, Pfizer Netherlands; Build and maintain sustainable relationships, negotiating price agreements and the promotion of all Pfizer-products with Dutch pharmacists and hospital pharmacists.

Maassluis, Netherlands

Clinical Sales rep, various products; finalisation of the traineeship by writing and presenting the brand operating plan of a cholesterol lowering product (a fibrate).

European Master In Law And Economics, Post Graduate Erasmus Program “Law And Economics”.

Post Graduate Erasmus Program “Law and Economics”: Rotterdam (Netherlands, Oct-Dec 1995) Ghent (Belgium, Jan-Mar 1996), Aix-en-Provence.

Leadership Course, Pfizer European Leadership Development Program

Pfizer Talent Program

Strategy Course, Strategy In The Pharmaceutical Industry

Pharma Educational Program

Masters, Economics

Business Economics, Erasmus University, Rotterdam. Degree: Master of Science

V.W.O, Atheneum

Secondary School